JAN 0 4 2002 &

Receipt

Attorney Docket No.: MPI1999-016CP1CN1(M)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Martin R. Hodge

Serial No.: 09/965,313

Filing Date: September 26, 2001 Group Art Unit: 1644

Title:

NOVEL IL-9/IL-2 RECEPTOR-LIKE MOLECULES AND USES THEREFOR

Assistant Commissioner of Patents P. O. Box 2327 Arlington, VA 22202

Attn: Application Processing Division

Correction Branch

## REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:

The Filing Receipt for the above-identified patent application incorrectly lists the Domestic Priority data as claimed by applicant. Applicant hereby requests, therefore, that the Domestic Priority data as claimed by applicant be corrected as follows: "This application is a CON of 09/574,100 filed May 18, 2000 which is a CIP of 09/313,913 filed May 19, 1999 ABN". A copy of the Filing Receipt with the changes noted thereon is submitted herewith. Please charge any underpayments or credit any overpayments to our Deposit Account No. 501668. A duplicate of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, Arlington, VA 22202on:

December 4, 2001

Date

Kerri Pollard Schray, Reg. No. 47,066

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.


Kerri Pollard Schray

Reg. No. 47,066

Agent for Applicant 75 Sidney Street

Cambridge, MA 02139

Telephone: (617) 551-3676 Facsimile: (617) 551-8820



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS **TOT CLAIMS** IND CLAIMS MPI1999-09/965,313 09/26/2001 1644 764 2 ~ 016CP1CN1 < 23 (M)

**CONFIRMATION NO. 5742** 

Millennium Pharmaceuticals, Inc. REC'D NOV 20 2001 75 Sidney Street Cambridge, MA 02139

11-20-01

**FILING RECEIPT** 

\*OC000000007078237\*

Date Mailed: 11/15/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Martin R. Hodge, Arlington, MA;

**Assignment For Published Patent Application** 

Millennium Pharmaceuticals, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/574,100 05/40/2000 \* 5/18/2000 WHICH IS A CIP OF 09/313,913 05/18/1999 ABN -(\*) Data inconsistent with PTO records.

**Foreign Applications** 

If Required, Foreign Filing License Granted 11/14/2001

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

Title

## LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).